Sustained-release naltrexone for opioid dependence.
Hege Kornør, Philipp Paul K Lobmaier, Nikolaj Kunøe
https://pubmed.ncbi.nlm.nih.gov/40342086/Actively Recruiting
Led by New York State Psychiatric Institute · Updated on 2026-05-19
180
Participants Needed
2
Research Sites
N/A
Total Duration
Researchers are evaluating a new approach to improve treatment for individuals with opioid use disorder by combining extended release naltrexone XR-naltrexone with buprenorphine-naloxone. The study aims to see if adding buprenorphine-naloxone can help reduce opioid cravings, improve mood, and increase how long people stay on XR-naltrexone treatment. This is a phase 23, double-blind, placebo-controlled trial involving adults aged 18 to 65 with opioid use disorder. Participants will receive XR-naltrexone injections every four weeks for 24 weeks, totaling six doses. After the first XR-naltrexone injection, they will be randomly assigned to take either buprenorphine-naloxone sublingual tablets daily or a placebo. The buprenorphine-naloxone dose will start after the initial XR-naltrexone injection and be gradually tapered off by the end of the study. Weekly medication management visits are included to monitor treatment. During the study, participants will undergo detoxification if needed and receive their first XR-naltrexone injection before randomization. Researchers will monitor treatment retention by measuring the proportion of participants receiving XR-naltrexone injections at 20 weeks. Assessments include medical history, physical exams, laboratory tests, and mood evaluations. The total study participation lasts 24 weeks, with careful monitoring throughout the treatment period.
CONDITIONS
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
A
Adam Bisaga, MD
O
Onumara Opara, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
New York State Psychiatric Institute
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Buprenorphine/naloxone plus extended-release naltrexone (XR-NTX) | Placebo plus extended-release naltrexone (XR-NTX) | Methadone or buprenorphine-naloxone maintenance (guideline-based standard care) |
|---|---|---|---|
| What is it? | Combination of daily sublingual buprenorphine/naloxone and monthly extended-release naltrexone injections, both given after successful opioid detoxification to prevent relapse. | Placebo sublingual tablets plus monthly extended-release naltrexone injections, after opioid detoxification for relapse prevention. | Long-term opioid agonist therapy with methadone or buprenorphine/naloxone, delivered in routine outpatient care, as the guideline-recommended standard approach for opioid use disorder. |
| Role in the trial or care pathway | This is the active, experimental combination tested for relapse prevention after XR-NTX induction. | Randomized comparator arm; receives identical XR-NTX with placebo sublingual tablet. | First-line standard of care for OUD, often used when antagonist-based relapse prevention is not selected or after failed antagonist trials. |
| Primary use | Intended to support abstinence and prevent opioid relapse in patients post-detoxification who have received XR-NTX. | Intended to measure baseline effectiveness of XR-NTX alone for relapse prevention. | Supports long-term abstinence, reduces opioid craving, withdrawal, and risk of relapse for adults with OUD. |
| How is it given or performed? | Daily sublingual tablet of buprenorphine/naloxone, plus monthly injection of XR-NTX (naltrexone) after detoxification. | Daily sublingual placebo tablet, plus monthly injection of XR-NTX after detoxification. | Methadone is taken daily under supervision, or buprenorphine/naloxone is taken daily, usually at home or pharmacy, with dosage individualized. |
| Evidence status | Efficacy and safety are currently under investigation; no published outcomes yet available for this combination approach. | Extended-release naltrexone alone has evidence for reducing relapse risk compared to placebo or no treatment, but retention and adherence may be challenging; evidence is evolving. | Methadone or buprenorphine-naloxone maintenance is backed by extensive evidence, including strong reductions in relapse and improved retention in care; remains the gold-standard treatment for most patients. |
| Important risks | Risks may include precipitated withdrawal (especially if not fully detoxified), potential medication interactions, liver enzyme changes, and possible adverse reactions to either drug; full safety profile not yet known for this combination. | Risks include possible injection site reaction, liver enzyme increases, and risk of overdose if opioids are resumed; lower risk of sedation or respiratory depression compared to agonists, but risk of nonadherence-related relapse and overdose is increased. | Risks of agonist therapy include sedation, respiratory depression (especially with overdose), drug interactions, misuse/diversion, and, for methadone, risk of QTc prolongation. |
| Important limitations | The approach is investigational, with no published data on effectiveness, safety, or comparative retention; challenges include unknown adherence and combination tolerability. | XR-NTX alone is associated with reduced retention compared to agonist therapy; clinical effectiveness may be limited by adherence barriers and increased relapse risk after missed doses. | Agonist therapy can be limited by need for daily medication, supervised dosing (especially for methadone), risk of misuse or diversion, stringent regulation, and potential stigma; not appropriate for patients seeking opioid-free approaches. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 24 weeks
Participants receive extended-release naltrexone injections every four weeks with daily sub-lingual buprenorphine-naloxone or placebo. Weekly medication management visits support treatment and monitor progress.
6 monthly XR-naltrexone injection visits and weekly medication management visits
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hege Kornør, Philipp Paul K Lobmaier, Nikolaj Kunøe
https://pubmed.ncbi.nlm.nih.gov/40342086/New York State Psychiatric Institute
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor